Serial No. Attorney Docket Number: FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office 8789-16CT to be assigned LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary) Applicants: Hill et al. Group Filing Date: concurrently herewith to be assigned **U. S. PATENT DOCUMENTS** Filing Date Examiner Document Name Class Subclass Number Date Initial Appropriate 55 167 ١. 3,230,142 1/18/66 Spero 424 240 12/30/69 Carstensen et al. 2. 3,487,152 239 424 3/24/70 ljzerman 3,502,772 3. 42 206 3,568,828 3/9/71 Lerner 4. 424 239 7/6/71 Jones et al. 3,591,688 242 424 2/1/72 Hendrix 3,639,600 6. 424 239 5/15/73 Segre 7. 3,733,407 424 238 3,795,734 3/5/74 Rochefort 8. 9/17/74 424 239 9. 3,836,651 Rudel et al. 260 397.4 05/28/74 Hofmeister et al. 10. 3,813,418 424 239 1/13/76 Segre 11. 3,932,635 239 Lachnit-Fixson 424 3,939,264 2/17/76 12. 3/9/76 Segre 206 534 13. 3,942,641 424 238 3,957,982 5/18/76 Lachnit-Fixson et al. 14. 239 424 Lachnit-Fixson 15. 3,969,502 7/13/76 Shroff 424 238 4,027,019 5/31/77 16. 1/3/78 Pasquale 424 243 17. 4,066,757 238 424 4,071,623 1/31/78 van der Vies 18. 238 424 Lachnit-Fixson et al. 19. 4,145,416 3/20/79 424 243 4,147,783 4/3/79 van der Vies 20. 424 175 5/15/79 Simoons 4,154,820 21. 239 7/1/80 424 4,210,644 Ewing et al. 22. 424 238 23. 4,259,325 3/31/81 Prezewowsky et al. 238 424 24. 4,291,028 9/22/81 Vorys 424 240 9/29/81 Vorys 25. 4,292,315

EXAMINER *EXAMINER

toadio

DATE CONSIDERED

2/18/03

	Paten OF DO	U.S. Department of and Trademark of CUMENTS CITE	Office D BY APPLIC	Attorney Docket Number: 8789-16CT			Serial No. to be assigned		
	(Us	e several sheets if	necessary)		Applicants: Hill et al.			<u> </u>	
					Filing Da	nte:		Group to be assigned	
Examiner Initial			Filing Date if Appropriate						
BB	26.	4,315,925	2/16/82	Hussain et al.	. 424	424	239		
1	27.	4,327,725	5/4/82	Cortese et al.		128	260		
!	28.	4,378,356	3/29/83	De Jager		424	238		
	29.	4,383,993	5/17/83	Hussain et al		424	239		
	30.	4,390,531	6/28/83	Edgren		424	239		
	31.	4,425,339	1/10/84	Pitchford		424	239		
	32.	4,512,986	4/23/85	Reel et al.		514	170		
	33.	4,530,839	7/23/85	Pasquale		514	171		
	34.	4,544,554	10/1/85	Pasquale		514	170		
	35.	4,616,006	10/7/86	Pasquale		514	170		
	36.	4,621,079	11/4/86	Lachnit-Fixs	on et al.	514	170		
	37.	4,628,051	12/9/86	Pasquale		514	170		
	38.	4,738,957	4/19/88	Laurent et al		514	182		
	39.	4,756,907	7/12/88	Beck et al.		424	85		
	40.	4,762,717	8/9/88	Crowley, Jr.		424	425		
	41.	4,764,378	8/16/88	Keith et al.	-	424	435		
	42.	4,783,337	11/8/88	Wong et al.		424	468		
-	43.	4,816,257	3/28/89	Buster et al.		424	430		
	44.	4,816,258	3/28/89	Nedberge et	al.	424	448		
	45.	4,826,831	5/2/89	Plunkett et a		514	170		
	46.	4,855,305	8/8/89	Cohen		514	171		
	47.	4,900,734	2/13/90	Maxson et a	1.	514	171		
	48.	4,914,089	4/3/90	Tax		514	170		
	49.	4,921,843	5/1/90	Pasquale		514	170		
	50.	4,962,098	10/9/90	Boissonneau	ılt	514	170		
P33	51.	4,977,147	12/11/90	Jungblut et a		514	171		

700dis

DATE CONSIDERED

2/18/50

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office					Attorney Docket Number: 8789-16CT			Serial No.
LIST	OF DO	CUMENTS CITE	D BY APPLIC				to be assigned	
	(Us	e several sheets if	necessary)					
				Applicants: Hill et al.				
				Filing Date: concurrently herewith			Group to be assigned	
Examiner Initial	-· I I				ame	Class	Subclass	Filing Date if Appropriate
BB	52.	5,006,345	4/9/91	Lang		424	467	
	53.	5,010,070	4/23/91	Boissonneaul	t	514	171	
	54.	5,043,331	8/27/91	Hirvonen et a	1.	514	170	
	55.	5,089,482	2/18/92	Hermens et a	l	514	58	
	56.	5,098,714	3/24/92	Wright et al.		424	473	
	57.	5,108,995	4/28/92	Casper	Casper		170	·
	58.	5,130,137	7/14/92	Crowley, Jr.		424	422	_
	59.	5,183,814	2/2/93	Dukes		514	171	
	60.	5,200,197	4/6/93	Wright et al.		424	473	
	61.	5,208,225	5/4/93	Boissonneault et al.		514	178	
	62.	5,210,081	5/11/93	Raveendranath et al.		514	179	
	63.	5,262,408	11/16/93	Bergink		514	182	
	64.	5,276,022	1/4/94	Casper		514	170	
	65.	5,280,023	1/18/94	Ehrlich et al.		514	177	
	66.	5,288,717	2/22/94	Raveendrana	th et al.	514	179	
	67.	5,362,720	11/8/94	Labrie		514	169	
	68.	5,382,573	1/17/95	Casper		514	170	
	69.	5,418,228	5/23/95	Bennink		514	182	
	70.	5,434,146	7/18/95	Labrie et al.		514	169	
	71.	5,464,871	11/1995	Kun et al.			617	
	72.	5,510,342	4/23/96	Washburn et	al.	514	179	
	73.	5,541,172	7/30/96	Labrie		514	169	
	74.	5,545,634	8/13/96	Labrie		514	169	
	75.	5,547,948	8/20/96	Barcomb		514	170	
	76.	5,567,695	10/22/96	Labrie		514	169	
BB	77.	5,629,303	5/13/97	Labrie et al.	_	514	169	

Badio

DATE CONSIDERED

2/18/05

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office					Attorney Docket Number: 8789-16CT		Serial No.	
LIST OF DOCUMENTS CITED BY APPLICANT								to be assigned
	(Us	e several sheets if	necessary)					
					Applicants:	Hill et al.		
			,	Filing Date: concurrently herewith			Group to be assigned	
Examiner Document Initial Number Date		N	ame o	Class	Subclass	Filing Date if Appropriate		
1313	78.	5,654,011	8/5/97	Jackson et al.		424	635	
	79.	5,753,639	5/19/98	Labrie		514	169	
	80.	5,759,576	6/2/98	Barcomb		424	479	
	81.	5,759,577	6/2/98	Barcomb		424	479	
	82.	5,807,586	9/15/98	Jackson et al.		424	630	
	83.	5,846,960	12/8/98	Labric		514	169	
	84.	5,861,387	1/19/99	Labrie et al.		514	169	
	85.	5,861,431	1/19/99	Hildebrand et	al.	514	557	
	86.	5,908,638	6/1/99	Huber et al.		424	465	
	87.	5,998,639	12/7/99	Raijmakers, e	et al.	552	625	
	88.	Re. 36,247	7/6/99	Plunkett et al	•	514	170	
300	89.	6,040,333	3/21/00	Jackson		514	456	
	•		FORE	GN PATENT I	DOCUMENTS			
7		Document Number	Date	Co	untry	Class	Subclass	Translation Yes No
BB	90.	IL25265	12/31/69	Israel			(X (Absract only)
7373	91.	1214712	12/2/70	Great Britain				
	92.	DT2431694 A1	3/4/76	Germany				х
	93.	DT2624025 A1	12/9/76	Germany				х
BB	94.	1561244	2/13/80	Great Britain				
1/	95.	GB2096462A	10/20/82	Great Britain				
BB	96.	DE3341638 A1	11/17/83	Germany				X (Abstract)

Bado

DATE CONSIDERED

2/18/05

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket Number: 8789-16CT	Serial No.			
	LIST	OF DOC	CUMENTS CITED BY APPLICANT		to be assigned			
		(Use	several sheets if necessary)					
			,	Applicants: Hill et al.				
				Filing Date: concurrently herewith	Group to be assigned			
			OTHER DOCUMENTS (Including Author	r, Title, Date, Pertinent Pages, Etc.)	1			
BU	3	97.		Late-Pregnancy Fluids: Extraction and Group Separation by Quantification by High-Performance Liquid 25 (1987).				
98. Fujino, ct al., 3-(Difluoro-1,3,5-trianinyl)-1 Derivation Reagent for Estrogens in High-1 37(7): 1939-1940 (1989).								
		99. /		nescent Derivation of Estrogens for HPLC Detection Coffinanceutics, Medical College of Virginia, APQ 1198.				
Performance Liquid Chromatog			Takadatc, et al., A Convenient Derivatization Performance Liquid Chromatographic Analy Chem. Pharm. Bull., 33(11): 5092-5095 (198	ysis. I. Derivatization of Estrogens with Da				
101. Novakovic, et al., High-Performance Liquid Chromatographic Determination of Equine Ultraviolet Absorbance and Electrochemical Detection, Journal of Chromatography A, 6 (1994).								
		102.	Townsend, et al., High-Performance Liquid in Tablets, Journal of Chromatography, 450:	d Chromatographic Determination of Conjugated Estrogens 0: 414-419 (1988).				
	Chromatography with Fluorescence Detect 104. Conjugated Estrogens, The United States			in Pregnancy Urine by High-Performance Liquid ction, Journal of Chromatography, 431: 249-257 (1988).				
			Conjugated Estrogens, The United States Pharmacopcia (USP), published by United States Pharmacopeial Convention, Inc., pp. 627-629 (2000).					
		105.	Synthetic Generic Conjugated Estrogens: Timeline, May 5, 1997, http://www.fda.gov/cder/news/cetimeline.htm .					
		106.	FDA Statement on Generic Premarin, HHS News Press Release, P97-12, May 5, 1997, http://www.fda.gov/cder/cepressrelease.htm .					
			New Drug Approval for Cenestin, Synthetic Answers, <a cder="" cebackground.htm"="" href="http://www.fda.gov/cder/news/cenes/</td><td colspan=5>tic Conjugated Estrogens, A: March 24, 1999, Questions and cenestin/qa.htm>.</td></tr><tr><td></td><td></td><td>108.</td><td>NDA 20-992 Cenestin<sup>™</sup> (synthetic conjugate 10 (1999).</td><td>ed estrogens, A) Tablets Physicians Packag</td><td>e Insert, pp. 1 -</td></tr><tr><td></td><td></td><td>109.</td><td>NDA 20-992 Cenestin<sup>™</sup> (synthetic conjugate (1999).</td><td>ed estrogens, A) Tablets Patient Package Ir</td><td>nsert, pp. 11 - 13</td></tr><tr><td></td><td></td><td>110.</td><td>FDA Backgrounder on Conjugated Estrogen http://www.fda.gov/cder/cebackground.htm					
BE	3	111.	Letter from Yana Ruth Mille, Chief, Comper Science, Center for Drug Evaluation & Rese General Counsel, The United States Pharmac O).	arch to Joseph G. Valentino, J.D., Senior V	ice President and			

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)			Attomey Docket Number: 8789-16CT	Serial No. to be assigned			
	(0	se several sheets if necessary)	Applicants: Hill et al.				
			Filing Date: concurrently herewith	Group to be assigned			
BE	5 112.	Letter from Yana Ruth Mille, Chief, Compensations, Center for Drug Evaluation & Rese General Counsel, The United States Pharmaco).	arch to Joseph G. Valentino, J.D., Senior V	ice President and			
	113.	Memorandum from Janet Woodcock, M.D., Douglas L. Sporn, Director, Office of Gener Version of Premarin (May 5, 1997).					
	114.	Sakac, Marijan N. et al., "Chemical Behavior of 3, 17.betadipropionoxy-9.alphahydroxyestra-1,3,5(10)-trien-6-one," DATABASE CHEMABS 'ONLINE!, Database accession no. 128:180573 XP002171996, J. Serb. Chem. Soc., 63(1): 21-24 (1998).					
	115.	Wiese, Thomas et al., "Induction of the Estrogen Specific Mitogenic Response of MCF-7 Cells by Selected Analogues of Estradiol-17β: A 3D Study," <i>Journal of Medicinal Chemistry</i> , 40 (22): 3659-3669 (1997).					
	116.	Yang et al., "The Hydroxylation and Amidat tetrakis(pentafluorophenyl)porphyrinato]mai					
BB	117.	Yang, Jerry et al., "Regioselective Oxidations of Equilenin Derivatives Catalyzed by a Rhodium(III) Porphyrin Complex-Contrast with the Manganese(III) Porphyrin," <i>Tetrahedron Letters</i> , 41 (42): 8063-8067 (2000).					
	118.	International Search Report corresponding to	PCT/US 01/07544; mailed on August-6, 2	2001-ref. reede			
137) 119.	Rzheznikov, V. M. et al., "Synthesis and Bio Oxidized for Rings B and C," <i>DATABASE C</i> XP002171997, KhimFarm. Zh. 22(12): 14	CHEMABS 'Online!, Database accession no				
	120.	Sakac, Marija N. et al., "Synthesis of New Steroidal N-butyl-N-methyl-undecanamide Derivatives," DATABASE CHEMABS 'Online!, Database accession no. 133:335378 XP002171995, ZB. MATICE SRP. PRIR. NAUKE 96: 5-9 (1999)					
	121.	Center for Drug Evaluation and Research (CDER), Guidance for Industry, Draft Guidance, Conjugated Estrogens, USP - LC-MS Method for Both Qualitative Chemical Characterization and Documentation of Qualitative Pharmaceutical Equivalence, March 2000, http://www.fda.gov/cder/guidance/index.htm .					
778 122. Physician's Desk Reference, 53: 3367-3379 (1999).							

Poadio

DATE CONSIDERED

2/18/05

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.